Blogs for May 2018

Novel Approaches to Improve Efficacy and Safety of CAR-T Therapy

Tuesday, May 29, 2018 - 08:44
CAR-T Therapy

By Jacqueline Carrico, BS, MD Candidate

Given the rapid advances in CAR-T therapy, there have been major efforts to improve the specificity and safety of these therapies. Very few targets exist that are only expressed in the malignant cell population, resulting in on-target/off-tumor toxicities. Most have been minor and controllable; however, several trials have been terminated due to severe and life-threatening toxicities. There is increasing concern about this problem with dually targeted therapies, such as dual-CAR or tandem CAR.

Synthetic Notch Receptors

One approach to increasing on-tumor specificity is the development of CAR-T cells that express synthetic...

Lysosomal Dysfunction is Linked to Exosomal Secretion

Tuesday, May 22, 2018 - 09:50
CAR-T Poster

By Christina Towers, PhD.

Lysosomal Dysfunction and Disease

Lysosomes are highly acidic organelles that are critical for cellular function and indispensable for degradative pathways like autophagy and endocytosis.  There are a number of different diseases that have been associated with lysosomal dysfunction, the most detrimental being neurological disorders including Huntington's Disease, Alzheimer's disease, and Parkinson's disease.  Other rare neurological diseases like Niemen-Pick disease Type C (NPC) have been directly linked to familial-mutations in endolysosomal genes.  All of these disorders are attributed to a buildup of the detrimental...

Targeting Success in CAR-T Therapy for Solid Tumors

Tuesday, May 15, 2018 - 09:40
CAR-T poster

By Jacqueline Carrico, BS, MD Candidate

Targeting Success in CAR-T Therapy for Solid Tumors

Developing successful CAR-T therapy requires identification of specific tumor-associated antigens, as the primary target for CAR-T binding and activation. Some solid tumors have well-characterized oncogenes which play a pivotal role in tumor cell proliferation, migration, and survival. These oncogenes are ideal targets for CAR-T therapy, particularly when the oncogene is expressed at low levels in normal tissues.

Epidermal Growth Factor Receptor (EGFR)

The tyrosine kinase receptor EGFR, is aberrantly expressed in non-small cell lung cancer (NSCLC),...

Mitochondrial ATPase inhibitory factor 1 (IF1) provides an explanation of cancer growth in anoxia or pseudo-anoxia

Tuesday, May 8, 2018 - 09:29
ATPase inhibitor factor 1 antibody ICC

By Jamshed Arslan Pharm.D.

Adenosine triphosphate (ATP) is the major life’s energy-carrying molecule. It is mainly produced by mitochondrial ATP synthase (Complex V) through oxidative phosphorylation (Oxphos). For example, Oxphos-dependent oxidation of a glucose molecule generates about 30 molecules of ATP. In Oxphos, respiratory chain (r.c.) complexes catalyze the transfer of electrons from energy-rich molecules (NADH or FADH2) to oxygen (O2) and...

TGF-beta for treating degenerative intervertebral disc disease

Tuesday, May 1, 2018 - 09:32
TGF-beta poster

By Jamshed Arslan Pharm.D.

Our upright posture and balance depend on a jelly-like material, called nucleus pulposus (NP), in the middle of intervertebral discs. NP cells protect us from disc degeneration by maintaining optimal amounts of proteoglycans (proteins bonded to glycosaminoglycans) in the NP matrix. This process can be facilitated by TGF-beta, which stimulates the synthesis of sulfated glycosaminoglycan (sGAG) and chondroitin sulfate proteoglycan 1 in the NP cells. The synthesis of sGAG depends on chondroitin polymerizing factor (ChPF), an enzyme that extends the chondroitin sulfate (CS) backbone in sGAG. However, the...

Blog Topics